Orange Book product · Generic (ANDA)
TAVABOROLE
TAVABOROLE
At a glance
Nov 25, 2020
Approved
Generic (ANDA)
Application
Not listed
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Nov 25, 2020
5 yr 8 mo ago
Today
Pharmaceutical detail
Active ingredient
TAVABOROLE
Strength
5%
Dosage form
SOLUTION
Route
TOPICAL
TE code
Not listed
Application
ANDA 212256
Product number
001
Marketing status
DISCN
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of TAVABOROLE
- 2014KERYDINBrand (NDA)
NDA 204427 · ANACOR PHARMS INC
- 2023TAVABOROLEGeneric (ANDA)
ANDA 212294 · ZYDUS LIFESCIENCES
- 2021TAVABOROLEGeneric (ANDA)
ANDA 212215 · SUN PHARMA CANADA
- 2021TAVABOROLEGeneric (ANDA)
ANDA 212224 · CIPLA
- 2021TAVABOROLEGeneric (ANDA)
ANDA 212168 · LUPIN
- 2021TAVABOROLEGeneric (ANDA)
ANDA 211963 · CHARTWELL RX
- 2020TAVABOROLEGeneric (ANDA)
ANDA 212188 · ALEMBIC
- 2020TAVABOROLEGeneric (ANDA)
ANDA 211297 · ENCUBE
- 2020TAVABOROLEGeneric (ANDA)
ANDA 211848 · PADAGIS US
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
